FindTrial
Sign In

SUMIRE

A Phase3, 12-week, Double-blind, Randmised, Parallel-group, Active-controlled, Multinational, Efficacy and Safety Study of Symbicort Turbuhaler 160/4.5mcg 2 Inhalations Bid Compared to Oxis Turbuhaler 4.5mcg 2 Inhalations Bid in Patients With Chronic Obstructive Pulmonary Disease

Status
Unknown
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080221041
Enrollment
Unknown
Registered
2010-03-16
Start date
2010-03-16
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Obstructive Pulmonary Disease (COPD)

Interventions

investigational material(s) Generic name etc : Budesonide/formoterol (ST) INN of investigational material : Budesonide/Formoterol Therapeutic category code : 229 Other agents affecting respiratory org

Sponsors

AstraZeneca
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: - A current clinical diagnosis of COPD - Documented COPD symptoms for more than 2 years - A smoking history of at least 10 pack years

Exclusion criteria

Exclusion criteria: - History and/or current clinical diagnosis of asthma - History and/or current clinical diagnosis of atopic diseases such as allergic rhinitis

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026